Efficacy and Safety of 20 mg/day Simvastatin in Patients with Renal Impairment and Combined Hyperlipidemia

每天使用20毫克Simvastatin於合併有混合型高脂血症的腎功能異常病人之效果評估

呂至剛(Jyh-Gang Leu) ； 黃美美(Mei-Mei Huang) ； 白榮貴(Jung-Kuei Pai) ； 江蔚文(Wey-Wen Jiang)

《輔仁醫學期刊》 3卷1期 (2005/06) Pp. 43-47

摘要

Background and purpose: We attempted to study the efficacy of 20 mg/day simvastatin as monotherapy in patients with renal impairment combined with hyperlipidemia. Methods: Thirty patients with impaired renal function (serum creatinine of ＞ 1.3 mg/dl, 17 of whom were dialysis patients) were studied. Twenty patients with normal renal function (serum creatinine of £ 1.3 mg/dl) were used as a control group. Once-daily 20 mg simvastatin was administered to all patients for 16 weeks in the absence of other lipid-lowering agents. Results: Serum total cholesterol (TC), triglycerides (TGs), and low-density lipoprotein-cholesterol (LDL-C) in both patient groups significantly decreased after simvastatin treatment (TC from 258±33 to 199±36 mg/dl, TGs from383±171 to 273±107mg/dl, and LDL-Cfrom150±36 to 101±33mg/dl in patients with impaired renal function; TC from 262±54 to 194±35 mg/dl, TG from 485±201 to 274±210 mg/dl, and LDL-C from118±41 to 101±27mg/dl in patientswith normal renal function, all p＜0.01). An increase in the serum high-density lipoprotein-cholesterol (HDL-C) also occurred in both patient groups (from 39±11 to 44±17mg/dl, p＜0.05 in patients with renal impairment), however, the change in patients with normal renal function was not significant (from 38±8 to 43±10 mg/dl, p=0.064). Conclusion: Monotherapy with 20 mg/day simvastatin has similar safety and effectiveness in patients with normal and those with impaired renal function.

關鍵字

降血脂藥物 ； 高血脂症 ； 腎功能不足

並列摘要

Background and purpose: We attempted to study the efficacy of 20 mg/day simvastatin as monotherapy in patients with renal impairment combined with hyperlipidemia. Methods: Thirty patients with impaired renal function (serum creatinine of ＞ 1.3 mg/dl, 17 of whom were dialysis patients) were studied. Twenty patients with normal renal function (serum creatinine of £ 1.3 mg/dl) were used as a control group. Once-daily 20 mg simvastatin was administered to all patients for 16 weeks in the absence of other lipid-lowering agents. Results: Serum total cholesterol (TC), triglycerides (TGs), and low-density lipoprotein-cholesterol (LDL-C) in both patient groups significantly decreased after simvastatin treatment (TC from 258±33 to 199±36 mg/dl, TGs from383±171 to 273±107mg/dl, and LDL-Cfrom150±36 to 101±33mg/dl in patients with impaired renal function; TC from 262±54 to 194±35 mg/dl, TG from 485±201 to 274±210 mg/dl, and LDL-C from118±41 to 101±27mg/dl in patientswith normal renal function, all p＜0.01). An increase in the serum high-density lipoprotein-cholesterol (HDL-C) also occurred in both patient groups (from 39±11 to 44±17mg/dl, p＜0.05 in patients with renal impairment), however, the change in patients with normal renal function was not significant (from 38±8 to 43±10 mg/dl, p=0.064). Conclusion: Monotherapy with 20 mg/day simvastatin has similar safety and effectiveness in patients with normal and those with impaired renal function.

並列關鍵字

Simvastatin ； Hyperlipidemia ； Renal impairment